Abstract | OBJECTIVE: METHODS: A total of 158 patients with active axial SpA were randomized (2:1) to receive 28 weeks of treatment with either infliximab 5 mg/kg plus naproxen 1,000 mg/day or placebo plus naproxen 1,000 mg/day. MRI of the sacroiliac (SI) joints and of the spine was performed at baseline and week 28. Images were scored for active inflammation and for fatty lesions. RESULTS: After 28 weeks, there was a significant reduction of inflammation in the spine and in the SI joints in both treatment groups, which was, however, more prominent in the infliximab plus naproxen group (mean ± SD spine osteitis change score -2.9 ± 5.1, versus -2.0 ± 4.2 in the placebo plus naproxen group [P < 0.001]; SI joint osteitis change score -4.3 ± 5.2 in the infliximab plus naproxen group versus -3.9 ± 3.7 in the placebo plus naproxen group [P = 0.003]). Similarly, there was a significant increase in the fatty lesion score after 28 weeks in both groups; this change did not, however, differ significantly between groups (spine fatty lesion change score 0.8 ± 1.7 in the infliximab plus naproxen group versus 1.0 ± 1.8 in the placebo plus naproxen group [P = 0.72]; SI joint fatty lesion change score 1.7 ± 2.7 in the infliximab plus naproxen group versus 1.4 ± 2.6 in the placebo plus naproxen group [P = 0.86]). CONCLUSION: These findings indicate that effective antiinflammatory treatment of axial SpA is associated with an increase in fatty lesion scores, independent of concomitant treatment with or without anti-TNF.
|
Authors | Denis Poddubnyy, Joachim Listing, Joachim Sieper |
Journal | Arthritis & rheumatology (Hoboken, N.J.)
(Arthritis Rheumatol)
Vol. 68
Issue 8
Pg. 1899-903
(08 2016)
ISSN: 2326-5205 [Electronic] United States |
PMID | 27015283
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016, American College of Rheumatology. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Naproxen
- Infliximab
|
Topics |
- Adipose Tissue
(pathology)
- Adolescent
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Antirheumatic Agents
(administration & dosage)
- Double-Blind Method
- Drug Therapy, Combination
- Humans
- Infliximab
(administration & dosage)
- Magnetic Resonance Imaging
- Middle Aged
- Naproxen
(administration & dosage)
- Sacroiliac Joint
- Spondylarthritis
(complications, diagnostic imaging, drug therapy)
- Young Adult
|